Pharmaceuticals Sector

Sumitomo Chemical started its pharmaceuticals business as the first Japanese company to manufacture synthetic pharmaceuticals based on its advanced organic synthesis technology. At present, the company is developing the Sector through Sumitomo Dainippon Pharma Co., Ltd., engaged in the prescription pharmaceuticals business, and Nihon Medi-Physics Co., Ltd., engaged in the diagnostic pharmaceuticals business.

Sumitomo Dainippon Pharma Co., Ltd.

  • Osaka Research Center

Sumitomo Dainippon Pharma Co., Ltd. pours all of its efforts into creating innovative new drugs in the Company’s focus research areas of Psychiatry & Neurology, Oncology, and Regenerative Medicine & Cell Therapy, where unmet medical needs are high, out of the sincere wish to provide innovative and effective pharmaceutical solutions to people not only in Japan, but also around the world. 

The Company operates its business mainly in Japan, North America, and China. In Japan, the focus marketing areas include Diabetes and Specialty areas (orphan drugs, etc.), as well as Psychiatry & Neurology. Some of its mainstay drugs are LONASEN® (atypical antipsychotic), TRERIEF® (therapeutic agent for Parkinson’s disease), and Trulicity® (therapeutic agent for type 2 diabetes). In North America, the Company markets LATUDA® (atypical antipsychotic), which is one of the core products of the Sumitomo Dainippon Pharma Group.

Nihon Medi-Physics Co., Ltd.

  • Dopamine transporter scintigrams by administration of DaTSCAN® injectable
    (The image data provided by Juntendo University Hospital)

Nihon Medi-Physics is the leading company in the highly specialized field of nuclear medicine in both diagnosis and therapy.
It offers a comprehensive range of functions from research and development to production, marketing and sales of radiopharmaceuticals used in diagnostic imaging procedures, such as SPECT for cerebral vascular disorders, dementia, cardiac diseases, and malignant tumors, as well as PET, which is considered useful for early detection of malignant tumors and large vessel vasculitis.
In the therapy field, it provides a radioactive seed for brachytherapy, and radiopharmaceutical product to palliate the pain caused by bone metastasis of cancers.
By bringing out further emerging potential and usefulness in nuclear medicine and molecular imaging procedures, Nihon Medi-Physics is moving steadily forward to materialize Theranostics (integration of therapeutics and diagnostics) concept in medical care practice, so that it can contribute to solving various issues that medical professional are currently confronting.